logo

For the Inventor, By the Inventor

Tewksbury, MA, United States of America

Edward R LaVallie

This inventor holds 42 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Secreted Proteins. Top assignees: Genetics Institute, Inc., Wyeth, Ono Pharmaceutical Co., Ltd.. Active years: 1989-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edward R LaVallie. Retrieved from https://idiyas.com/inventor/edward-r-lavallie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 

% Patents Active = 83.3


Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 352(Granted Patents)


Location History:

  • Melrose, MA (US) (1989)
  • Tewskbury, MA (US) (1998)
  • Tewksbury, MA (US) (1993 - 2004)
  • Harvard, MA (US) (1999 - 2009)

Company Filing History:

goldMedal34 out of 392 
 
Genetics Institute, Inc.
 patents
silverMedal6 out of 1,309 
 
Wyeth
 patents
bronzeMedal1 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents
4. 1 out of 834,513 
Other
 patents

Years Active: 1989-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Protein Kinase C Zeta
Aggrecanase Structure
Secreted Proteins
Polynucleotides
Enterokinase
Angiogenesis Inhibition
Peptide Fusions
Human SDF-5
Chordin Compositions
Modified ADAMTS4
Human Semaphorin E
Protein Recovery
42 patents (USPTO):Explore Patents
1. 7638482 - Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases (2009-12-29),
2. 7625731 - Aggrecanase structure (2009-12-01),
3. 7615363 - Aggrecanase structure (2009-11-10),
4. 7344861 - Secreted proteins and polynucleotides encoding them (2008-03-18),
5. 7223858 - Truncated aggrecanase molecules (2007-05-29),
6. 7118902 - Modified ADAMTS4 molecules and method of use thereof (2006-10-10),
7. 7078217 - Aggrecanase molecules (2006-07-18),
8. 7026445 - Human SDF-5 protein and compositions (2006-04-11),
9. 6746859 - Cloning of enterokinase and method of use (2004-06-08),
10. 6312921 - Secreted proteins and polynucleotides encoding them (2001-11-06),
11. 6280739 - Method of inhibiting angiogenesis using secreted proteins (2001-08-28),
12. 6143524 - Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, (2000-11-07),
13. 6084071 - Human L105 polypeptides and polynucleotides encoding same (2000-07-04),
14. 5986056 - Chordin compositions (1999-11-16),
15. 5985602 - Secreted proteins and polynucleotides encoding them (1999-11-16),

Title: The Innovative Journey of Edward R LaVallie

Introduction: Edward R LaVallie, a talented inventor hailing from Tewksbury, MA (US), has made significant contributions to the field of innovations with his creative mind and dedication.

Latest Patents: Edward R LaVallie holds several patents in various technological domains, showcasing his versatility and expertise in inventing cutting-edge solutions to real-world problems.

Career Highlights: Throughout his illustrious career, Edward R LaVallie has demonstrated a keen eye for identifying gaps in the market and developing unique inventions to fill those voids. His innovative spirit has led to the creation of groundbreaking technologies that have revolutionized industries.

Collaborations: Edward R LaVallie has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: In conclusion, Edward R LaVallie's passion for innovation, coupled with his technical expertise, has established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators to push the boundaries of what is possible.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…